scholarly journals Additional Reduction of Residual Symptoms with Aripiprazole Augmentation in the Patients with Partially Remitted Major Depressive Disorder

2021 ◽  
Vol 19 (2) ◽  
pp. 243-253
Author(s):  
Cheolmin Shin ◽  
Chi-Un Pae ◽  
Kyung Phil Kwak ◽  
Sang Won Jeon ◽  
Hyun-Ghang Jeong ◽  
...  
Keyword(s):  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Major Depressive ◽  
Residual Symptoms ◽  
Additional Reduction

Suicidal ideation and other persisting symptoms after CBT or antidepressant medication treatment for major depressive disorder

2018 ◽  
Vol 49 (11) ◽  
pp. 1869-1878 ◽  
Author(s):  
Boadie W. Dunlop ◽  
Philip E. Polychroniou ◽  
Jeffrey J. Rakofsky ◽  
Charles B. Nemeroff ◽  
W. Edward Craighead ◽  
...  
Keyword(s):  
Major Depressive Disorder ◽  
Suicidal Ideation ◽  
Depressive Disorder ◽  
Rating Scale ◽  
Antidepressant Medication ◽  
Major Depressive ◽  
Residual Symptom ◽  
Residual Symptoms ◽  
Antidepressant Medications ◽  
Item Scores

AbstractBackgroundPersisting symptoms after treatment for major depressive disorder (MDD) contribute to ongoing impairment and relapse risk. Whether cognitive behavior therapy (CBT) or antidepressant medications result in different profiles of residual symptoms after treatment is largely unknown.MethodsThree hundred fifteen adults with MDD randomized to treatment with either CBT or antidepressant medication in the Predictors of Remission in Depression to Individual and Combined Treatments (PReDICT) study were analyzed for the frequency of residual symptoms using the Montgomery Asberg Depression Rating Scale (MADRS) item scores at the end of the 12-week treatment period. Separate comparisons were made for treatment responders and non-responders.ResultsAmong treatment completers (n= 250) who responded to CBT or antidepressant medication, there were no significant differences in the persistence of residual MADRS symptoms. However, non-responders treated with medication were significantly less likely to endorse suicidal ideation (SI) at week 12 compared with those treated with CBT (non-responders to medication: 0/54, 0%, non-responders to CBT: 8/30, 26.7%;p= .001). Among patients who terminated the trial early (n= 65), residual MADRS item scores did not significantly differ between the CBT- and medication-treated groups.ConclusionsDepressed adults who respond to CBT or antidepressant medication have similar residual symptom profiles. Antidepressant medications reduce SI, even among patients for whom the medication provides little overall benefit.

Number of illness episodes as predictor of residual symptoms in major depressive disorder

2018 ◽  
Vol 262 ◽  
pp. 469-476 ◽  
Author(s):  
Gianluca Serafini ◽  
Jacopo Nebbia ◽  
Nicolò Cipriani ◽  
Claudia Conigliaro ◽  
Denise Erbuto ◽  
...  
Keyword(s):  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Major Depressive ◽  
Residual Symptoms

Residual symptoms after remission of major depressive disorder with fluoxetine and risk of relapse

2010 ◽  
Vol 28 (2) ◽  
pp. 137-144 ◽  
Author(s):  
Nadia Iovieno ◽  
Adrienne van Nieuwenhuizen ◽  
Alisabet Clain ◽  
Lee Baer ◽  
Andrew A. Nierenberg
Keyword(s):  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Major Depressive ◽  
Residual Symptoms ◽  
Risk Of Relapse

Modafinil Augmentation of SSRI Therapy in Patients with Major Depressive Disorder and Excessive Sleepiness and Fatigue: A 12-Week, Open-label, Extension Study

CNS Spectrums ◽  
2006 ◽  
Vol 11 (2) ◽  
pp. 93-102 ◽  
Author(s):  
Michael E. Thase ◽  
Maurizio Fava ◽  
Charles DeBattista ◽  
Sanjay Arora ◽  
Rod J. Hughes
Keyword(s):  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Clinical Global Impression ◽  
Rating Scale ◽  
Extension Study ◽  
Dose Titration ◽  
Open Label ◽  
Major Depressive ◽  
Residual Symptoms ◽  
Excessive Sleepiness

AbstractIntroduction:Many patients with major depressive disorder (MDD) treated with selective serotonin reuptake inhibitors have residual symptoms (eg, persistent fatigue, excessive sleepiness) despite an overall antidepressant response. Placebo-controlled studies indicate that modafinil, a wake-promoting agent, may relieve residual symptoms.Methods:This 12-week, open-label, dose titration, extension study followed an 8-week placebo-controlled study of modafinil augmentation in patients with MDD. The dose was 100–400 mg/day. The median stable dose was 300 mg/day. Assessments were the Epworth Sleepiness Scale, Brief Fatigue Inventory, Clinical Global Impression of Improvement scale, 17-item Hamilton Rating Scale for Depression, and Montgomery-Åsberg Depression Rating Scale.Results:Of the 245 patients treated, 194 completed the study; 70% reported Clinical Global Impression of Improvement scale responses of “much improved” or “very much improved” between open-label baseline and final visit (previous randomized modafinil group: 74%; placebo group: 66%). When data were analyzed for four subsets of patients (former modafinil responders, placebo responders, modafinil nonresponders, and placebo nonresponders), improvements in scores on all outcome measures were at least twice as great among former modafinil and placebo nonresponders compared with responders. Most common adverse events were headache (18%), nausea (9%), and dizziness (7%); all were generally mild to moderate in severity.Conclusion:Twelve weeks of modafinil augmentation relieved excessive sleepiness, reduced fatigue, and improved patients' overall clinical condition, including mood.

Major Depressive Disorder: Recurrence Risk Factors

2017 ◽  
Vol 41 (S1) ◽  
pp. S139-S139
Author(s):  
R. Ben Soussia ◽  
S. Khouadja ◽  
I. Marrag ◽  
S. Younes ◽  
M. Nasr
Keyword(s):  
Risk Factors ◽  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Age At Onset ◽  
Recurrence Risk ◽  
University Hospital ◽  
Major Depressive ◽  
Residual Symptoms ◽  
Time To Recurrence ◽  
Depressive Episodes

IntroductionIn spite of the frequency and the gravity of the depressive episodes, the major depressive disorder (MDD) is diagnosed and treated today insufficiently and the risk factors of its recurrence are little approached.Aims of the studyDescribe the socio–demographic, clinical and therapeutic characteristics of patients with MDD and identify the factors involved in the recurrence risk.MethodologyThis is a retrospective study carried out in the university hospital of Mahdia, Tunisia during two years. We have included patients with a follow up for at least two years and diagnosed with MDD, isolated episode or MDD, recurrent episode according to the DSM-IV-TR criteria. Data collection was performed using two pre-established questionnaires respectively with 51 and 92 items. We have estimated the time to recurrence with the Kaplan-Meier estimator.ResultsWe have collected 150 patients. The time to recurrence was 109 months. Five factors were associated with recurrence: early age at onset of the disorder, family history of mood disorders, severity of the index major depressive episode, persistent residual symptoms and ceasing treatment.ConclusionDepression is a very common mental illness that is highly recurrent in individuals. There is great interest in the development of strategies that might reduce the recurrence of depression.

Sign in / Sign up

Export Citation Format

Share Document